Scope
The ACG biliary-stricture guideline separates diagnosis from drainage and distinguishes benign extrahepatic disease, extrahepatic malignancy and perihilar obstruction. The location and suspected cause determine how to obtain tissue, whether drainage is necessary and which stent strategy is appropriate. Perihilar procedures require particular planning to protect transplant options and drain enough functioning liver. Several comparisons remain uncertain, so the summary retains conditional recommendations and evidence gaps.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Choose the tissue-acquisition route carefully
- For an extrahepatic stricture associated with a suspected or visible pancreatic mass, prefer EUS-guided fine-needle tissue acquisition over ERCP sampling to investigate malignancy. ACG gives this a strong recommendation with moderate-quality evidence. [1]
- When the pancreatic-mass patient is asymptomatic or minimally symptomatic and diagnosis plus drainage are needed, consider EUS and ERCP in one session. Acute cholangitis or significant symptoms justify expedient ERCP instead of waiting for a combined procedure. [1]
- For EUS sampling of a pancreatic-mass-associated extrahepatic stricture, consider fine-needle biopsy or fine-needle aspiration with rapid on-site evaluation over aspiration without that support. This is conditional and based on very-low-quality evidence. [1]
- For suspected perihilar cholangiocarcinoma, avoid EUS-guided or percutaneous needle biopsy of the primary stricture or mass. Favor intraductal sampling; needle sampling can target associated lymphadenopathy. The primary-lesion restriction matters because transplant eligibility can be affected. [1]
- At the first ERCP for a suspected malignant perihilar stricture, use multimodality sampling rather than brush cytology alone. ACG strongly recommends this despite low-quality evidence. [1]
- If multimodality ERCP sampling leaves the diagnosis uncertain, select additional tests according to the clinical context, stricture characteristics and resources. A nondiagnostic initial investigation is not a definitive benign diagnosis. [1]
Plan durable treatment and stent removal
- For a benign extrahepatic stricture, ACG conditionally favors a fully covered self-expanding metal stent over multiple parallel plastic stents to reduce the number of treatment procedures. Evidence quality is low. [1]
- Treat a benign extrahepatic stricture for 12 months with multiple plastic stents or at least 6 months with a fully covered metal stent. Some evidence favors 12 months of metal-stent treatment; if planning that duration, consider exchange at 6 months to reduce embedment risk. [1]
- When the gallbladder remains in situ and a metal stent cannot avoid the cystic-duct opening, consider multiple plastic stents instead. Covering that opening may increase acute cholecystitis risk. [1]
Avoid unnecessary preoperative drainage and choose stents appropriately
- Do not routinely drain an extrahepatic obstruction before surgery for resectable pancreatic cancer or cholangiocarcinoma. Drainage is warranted selectively, including acute cholangitis, severe pruritus, very high bilirubin, neoadjuvant treatment or an anticipated surgical delay. This recommendation against routine drainage is conditional. [1]
- For unresectable or borderline-resectable malignant extrahepatic strictures, use a self-expanding metal stent rather than a plastic stent. ACG strongly recommends this with moderate-quality evidence. [1]
- Confirm malignancy before placing an uncovered metal stent across a biliary stricture. Clinical suspicion alone is insufficient for this step because the uncovered device can become permanently embedded. [1]
- If an uncovered metal stent is used in a potential pancreaticoduodenectomy candidate, place its upstream end at least 1.5 cm below the biliary confluence to preserve the operative approach. [1]
- For unresectable or borderline-resectable extrahepatic malignancy, evidence does not establish whether uncovered or fully covered metal stents are preferable. Do not turn the metal-versus-plastic recommendation into a universal covered-stent preference. [1]
Plan drainage around liver sectors and clinical goals
- For otherwise asymptomatic obstructive jaundice from malignant perihilar disease when further treatment has been declined or is not possible, palliative drainage is an individualized decision rather than mandatory. [1]
- Evidence is insufficient to favor ERCP over percutaneous transhepatic drainage for suspected malignant perihilar strictures. If ERCP is selected, use an endoscopist with advanced biliary training or experience. [1]
- Before perihilar ERCP, review cross-sectional imaging and plan careful contrast injection and fluoroscopy. Give antibiotics when opacified ducts may drain slowly or incompletely. [1]
- Plan perihilar drainage by liver sector and volume, aiming to drain more than 50% of the nonatrophic liver. A simple unilateral-versus-bilateral label does not define whether sufficient liver is drained. [1]
- Evidence is insufficient to choose plastic over uncovered metal stents universally for malignant perihilar disease. If choosing metal stents, first demonstrate an effective drainage strategy with plastic stents. [1]
Consider specialist adjuncts and rescue drainage
- For malignant perihilar cholangiocarcinoma in people ineligible for resection or transplantation, consider photodynamic therapy or radiofrequency ablation alongside plastic stenting rather than plastic stenting alone. This is conditional with low-quality evidence. [1]
- When indicated ERCP fails or is impossible, consider EUS-guided access or drainage over percutaneous transhepatic drainage only when an endoscopist has substantial interventional-EUS experience. The recommendation is conditional with very-low-quality evidence and reflects fewer adverse events. [1]
Limitations and use
- This is not a procedural manual or a complete cancer-staging, transplant-eligibility or acute-cholangitis pathway. Device sizing, antibiotic regimens and rescue techniques require specialist planning.
- The guidance distinguishes benign from malignant and extrahepatic from perihilar strictures; stent recommendations should not be transferred indiscriminately between these groups.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Diagnosis and Management of Biliary Strictures
Selected recommendation material consulted
Publication details
- Issuing organisation
- ACG
- Resource type
- Clinical guideline · House clinical summary
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.